Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Июль 22, 2024
Abstract
Rheumatoid
arthritis
(RA)
is
an
autoimmune
disease
with
multifactorial
etiology
and
intricate
pathogenesis.
In
RA,
repeated
monotherapy
frequently
associated
inadequate
efficacy,
drug
resistance,
severe
side
effects.
Therefore,
a
shift
has
occurred
in
clinical
practice
toward
combination
therapy.
However,
conventional
therapy
encounters
several
hindrances,
including
low
selectivity
to
arthritic
joints,
short
half-lives,
varying
pharmacokinetics
among
coupled
drugs.
Emerging
nanotechnology
offers
incomparable
opportunity
for
developing
advanced
against
RA.
First,
it
allows
co-delivering
multiple
drugs
augmented
physicochemical
properties,
targeted
delivery
capabilities,
controlled
release
profiles.
Second,
enables
therapeutic
nanomaterials
development,
thereby
expanding
regimens
include
multifunctional
nanomedicines.
Lastly,
facilitates
the
construction
of
all-in-one
nanoplatforms
assembled
modalities,
such
as
phototherapy,
sonodynamic
therapy,
imaging.
Thus,
promising
solution
current
bottleneck
both
RA
treatment
diagnosis.
This
review
summarizes
rationale,
advantages,
recent
advances
nano-empowered
It
also
discusses
safety
considerations,
drug–drug
interactions,
potential
translation.
Additionally,
provides
design
tips
outlook
on
future
developments
The
objective
this
achieve
comprehensive
understanding
mechanisms
underlying
unlock
maximum
nanotechnology,
facilitating
smooth
transition
research
findings
from
laboratory
practice.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Янв. 1, 2024
Abstract
Combining
existing
drug
therapy
is
essential
in
developing
new
therapeutic
agents
disease
prevention
and
treatment.
In
preclinical
investigations,
combined
effect
of
certain
known
drugs
has
been
well
established
treating
extensive
human
diseases.
Attributed
to
synergistic
effects
by
targeting
various
pathways
advantages,
such
as
reduced
administration
dose,
decreased
toxicity,
alleviated
resistance,
combinatorial
treatment
now
being
pursued
delivering
combat
major
clinical
illnesses,
cancer,
atherosclerosis,
pulmonary
hypertension,
myocarditis,
rheumatoid
arthritis,
inflammatory
bowel
disease,
metabolic
disorders
neurodegenerative
Combinatorial
involves
combining
or
co-delivering
two
more
for
a
specific
disease.
Nanoparticle
(NP)-mediated
delivery
systems,
i.e.,
liposomal
NPs,
polymeric
NPs
nanocrystals,
are
great
interest
wide
range
due
targeted
delivery,
extended
release,
higher
stability
avoid
rapid
clearance
at
infected
areas.
This
review
summarizes
targets
diseases,
clinically
approved
combinations
the
development
multifunctional
emphasizes
strategies
based
on
severe
Ultimately,
we
discuss
challenging
NP-codelivery
translation
provide
potential
approaches
address
limitations.
offers
comprehensive
overview
recent
cutting-edge
NP-mediated
combination
Biomedicine & Pharmacotherapy,
Год журнала:
2022,
Номер
151, С. 113126 - 113126
Опубликована: Май 26, 2022
Rheumatoid
arthritis
(RA)
is
one
of
more
than
100
types
arthritis.
This
chronic
autoimmune
disorder
affects
the
lining
synovial
joints
in
about
0.5%
people
and
may
induce
severe
deformity
disability.
RA
impacts
health
life
from
all
sexes
ages
with
prevalence
elderly
women
people.
Significant
improvement
has
been
noted
last
two
decades
revealing
mechanisms
development
RA,
early
diagnosis
new
treatment
options.
Non-steroidal
anti-inflammatory
drugs
(NSAIDs),
corticosteroids,
disease-modifying
antirheumatic
(DMARDs)
remain
most
known
treatments
used
against
RA.
However,
not
patients
respond
well
to
these
therefore,
solutions
are
immense
need
improve
disease
outcomes.
In
present
review,
we
discuss
highlight
recent
findings
concerning
different
classes
therapies
including
conventional
modern
drug
therapies,
as
emerging
options
phyto-cannabinoid
cell-
RNA-based
therapies.
A
better
understanding
their
pathways
might
help
find
a
specific
target
inflammation,
cartilage
damage,
reduce
side
effects
ACS Nano,
Год журнала:
2023,
Номер
17(5), С. 4358 - 4372
Опубликована: Фев. 27, 2023
The
synovial
tissues
under
rheumatoid
arthritis
conditions
are
usually
infiltrated
by
inflammatory
cells,
particularly
M1
macrophages
with
aberrant
redox
homeostasis,
which
causes
rapid
deterioration
of
articular
structure
and
function.
Herein,
we
created
an
ROS-responsive
micelle
(HA@RH-CeOX)
through
the
in
situ
host–guest
complexation
between
ceria
oxide
nanozymes
hyaluronic
acid
biopolymers,
precisely
delivered
nanozyme
clinically
approved
drug
Rhein
(RH)
to
proinflammatory
macrophage
populations
inflamed
tissues.
abundant
cellular
ROS
could
cleave
thioketal
linker
trigger
release
RH
Ce.
Specifically,
Ce3+/Ce4+
pair
present
SOD-like
enzymatic
activity
rapidly
decompose
alleviate
oxidative
stress
macrophages,
while
inhibit
TLR4
signaling
both
act
a
concerted
manner
induce
their
repolarization
into
anti-inflammatory
M2
phenotype
ameliorate
local
inflammation
promote
cartilage
repair.
Notably,
rats
bearing
showed
drastic
increase
M1-to-M2
ratio
from
1:0.48
1:1.91
tissue
significantly
reduced
cytokine
levels
including
TNF-α
IL-6
following
intra-articular
injection
HA@RH-CeOX,
accompanied
efficient
regeneration
restored
Overall,
this
study
revealed
approach
modulate
homeostasis
reprogram
polarization
states
micelle-complexed
biomimetic
enzymes,
offers
alternative
opportunities
for
treatment
arthritis.
Journal of Functional Biomaterials,
Год журнала:
2025,
Номер
16(1), С. 24 - 24
Опубликована: Янв. 14, 2025
Autoimmune
diseases
present
complex
therapeutic
challenges
due
to
their
chronic
nature,
systemic
impact,
and
requirement
for
precise
immunomodulation
avoid
adverse
side
effects.
Recent
advancements
in
biodegradable
stimuli-responsive
nanomaterials
have
opened
new
avenues
targeted
drug
delivery
systems
capable
of
addressing
these
challenges.
This
review
provides
a
comprehensive
analysis
state-of-the-art
nanocarriers
such
as
polymeric
nanoparticles,
liposomes,
hydrogels
engineered
autoimmune
therapies.
These
are
designed
degrade
safely
the
body
while
releasing
agents
response
specific
stimuli,
including
pH,
temperature,
redox
conditions,
enzymatic
activity.
By
achieving
localized
controlled
release
anti-inflammatory
immunosuppressive
agents,
minimize
toxicity
enhance
efficacy.
We
discuss
underlying
mechanisms
nanomaterials,
recent
applications
treating
rheumatoid
arthritis,
multiple
sclerosis,
inflammatory
bowel
disease,
design
considerations
essential
clinical
translation.
Additionally,
we
address
current
challenges,
biocompatibility,
scalability,
regulatory
hurdles,
well
future
directions
integrating
advanced
nanotechnology
with
personalized
medicine
treatment.
highlights
transformative
potential
presenting
them
promising
strategy
advance
precision
improve
patient
outcomes
disease
management.
Acta Materia Medica,
Год журнала:
2023,
Номер
2(1)
Опубликована: Янв. 18, 2023
Rheumatoid
arthritis
is
a
systemic
inflammatory
disease
that
can
lead
to
articular
cartilage
destruction
and
periarticular
bone
erosion,
thus
ultimately
compromising
joint
integrity
function.
Anti-inflammatory
drugs
biological
agents
are
commonly
used
treat
rheumatoid
arthritis,
but
they
cannot
selectively
target
inflamed
joints,
because
of
their
mechanisms,
short
half-lives
low
bioavailability.
Consequently,
these
must
be
at
high
doses
delivered
frequently,
thereby
increasing
costs
the
risk
adverse
effects.
Drug
delivery
systems,
such
as
nanoparticles,
liposomes
micelles,
significantly
prolong
drug
half-life
in
body
enable
targeted
into
joints.
In
this
review,
we
comprehensively
describe
pathogenesis
clinical
diagnosis
summarize
recent
advances
therapeutic
strategies,
particularly
nano-targeting
systems
for
arthritis.
Background
and
purpose:
Flavonoids
are
a
group
of
phytochemicals
found
abundantly
in
various
plants.
Scientific
evidence
has
revealed
that
flavonoids
display
potential
biological
activities,
including
their
ability
to
alleviate
inflammation.
This
activity
is
closely
related
action
blocking
the
inflammatory
cascade
inhibiting
production
pro-inflammatory
factors.
However,
as
typically
have
poor
bioavailability
pharmacokinetic
profile,
it
quite
challenging
establish
these
compounds
drug.
Nevertheless,
progressive
advancements
drug
delivery
systems,
particularly
nanotechnology,
shown
promising
approaches
overcome
such
challenges.
Review
approach:
narrative
review
provides
an
overview
scientific
knowledge
about
mechanism
mitigation
reaction
prior
delivering
comprehensive
discussion
opportunity
nanotechnology-based
system
preparation
flavonoid-based
Key
results:
Various
studies
conducted
silico,
vitro,
vivo,
clinical
trials
deciphered
anti-inflammatory
activities
linked
modulate
biochemical
mediators,
enzymes,
signalling
pathways
involved
processes.
compound
could
be
encapsulated
nanotechnology
platforms
increase
solubility,
bioavailability,
pharmacological
well
reduce
toxic
effects
compounds.
Conclusion:
Summary,
we
conclude
derivates
given
results
development
new
candidates,
especially
if
they
formulate
nanoparticles.
